SCHEMBL1782540

SCHEMBL1782540

CCOC(=O)C1C(=O)CC(C)CC1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
ALOX12 P18054 1/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
POLB P06746 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
TP53 P04637 1/20 0.37
NPEPPS P55786 2/20 0.37
HTT P42858 2/20 0.36
TSHR P16473 1/20 0.36
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11676672 0.79 ALDH1A1 (0.49) ALDH1A1ALOX12MEN1KMT2AKDM4E
SCHEMBL9729328 0.77 ALDH1A1 (0.45) ALDH1A1ALOX12MEN1KMT2AKDM4E
SCHEMBL9729321 0.77 ALDH1A1 (0.45) ALDH1A1ALOX12MEN1KMT2AKDM4E
SCHEMBL4846520 0.77 ALDH1A1 (0.56) ALDH1A1ALOX12MEN1KMT2AKDM4E
SCHEMBL1262342 0.76 ALDH1A1 (0.41) ALDH1A1ALOX12MEN1KMT2AKDM4E
SCHEMBL680912 0.76 ALDH1A1 (0.41) ALDH1A1ALOX12MEN1KMT2AKDM4E
SCHEMBL27905418 0.76 ALDH1A1 (0.41) ALDH1A1ALOX12MEN1KMT2AKDM4E
SCHEMBL8502739 0.75 ALDH1A1 (0.54) ALDH1A1ALOX12MEN1KMT2AKDM4E
SCHEMBL5796691 0.73 ALDH1A1 (0.42) ALDH1A1ALOX12MEN1KMT2AKDM4E
SCHEMBL1415765 0.72 ALDH1A1 (0.46) ALDH1A1ALOX12MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507559-B2 Cyclohexenyl modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-13 US disclosed
EP-2318352-B1 CYCLOHEXENYL COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL MYERS SQUIBB CO (US) 2012-12-19 EP disclosed
US-20110118354-A1 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2011-05-19 US disclosed
EP-2318352-A2 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY Bristol-Myers Squibb Company (US) 2011-05-11 EP disclosed
WO-2010009068-A2 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118354-A1 CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY CCR1, CCR2, CCR3 ALDH1A1 917/4885ALOX12 1056/4885MEN1 4508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.